NCT07649031
MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia Patients
Recruiting
Not specifiedAges 18+ObservationalUniversity of MinnesotaInvestigator-initiated
~80 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:MRIs
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
sensitivity of mMRI and ddMRI in identifying dysplastic and malignant lesions in FA patients.
Measured over Immediately after MRI
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Rachel Uppgaard · PRINCIPAL_INVESTIGATOR · University of Minnesota
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients with a diagnosis of Fanconi Anemia who are willing to participate and willing to have MRIs
Willing to provide informed consent
Exclusion
Patient without diagnosis of FA
Patients with FA who are under the age of 18
Unable to tolerate any MRI due to claustrophobia
Any contraindication for the MRI
Unable to provide informed consent or comply with the study protocol
What this trial measures
- sensitivity of mMRI and ddMRI in identifying dysplastic and malignant lesions in FA patients.Immediately after MRI
Proportion of positive lesions correctly diagnosed
- specificity of mMRI and ddMRI in identifying dysplastic and malignant lesions in FA patients.Immediately after MRI
Proportion of negative lesions correctly diagnosed